WOBURN, MA / ACCESSWIRE / April 28, 2023 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will report financial results for the three months ended March 31, 2023 on Friday, May 12, 2023. The results will be released before the market opens and the company will host a conference call at 8:30AM Eastern Time.
Conference call: Friday, May 12, 2023 at 8:30AM ET
Toll Free: 888-506-0062
International: 973-528-0011
Access Code: 104591
Webcast: https://www.webcaster4.com/Webcast/Page/2948/48139
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and Twitter.
Contacts:
Biofrontera Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.84 |
| Daily Volume: | 0 |
| Market Cap: | US$6.480M |
March 21, 2025 December 03, 2024 November 22, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
